Objective: Bronchopulmonary dysplasia (BPD) in preterm infants is associated with impaired alveolar growth, inflammation and airway hyperreactivity. In animal models of BPD, inhaled nitric oxide (NO) improves alveolar growth and inhibits airway smooth muscle proliferation. This study was designed to assess the effect of inhaled NO on resistance and compliance in ventilated preterm infants with evolving BPD.
Introduction
Despite marked improvement in neonatal care, bronchopulmonary dysplasia (BPD) continues to be a major cause of morbidity in very low birth weight infants. This morbidity includes prolonged hospitalization, pulmonary complications and adverse neurodevelopmental outcome. 1 Although multiple factors contribute to BPD, exposure to high supplemental oxygen and mechanical ventilation are the key factors in inducing lung injury. 2 The pathologic features of this disease include impaired alveolar growth, inflammation and structural abnormalities of both the pulmonary circulation and airways. [2] [3] [4] These structural changes have been associated with pulmonary hypertension, 4 increased airway resistance 5 and subsequent airway hyperreactivity. In the preterm baboon model of BPD, inhaled nitric oxide (NO) has been shown to normalize elastin deposition 6 and improve lung volume, dynamic lung compliance and expiratory resistance (Rexp). 6 In premature lambs with BPD, NO decreases alveolar hypoplasia 7 and inhibits airway smooth muscle proliferation. 7 Nitric oxide exposure has also been associated with decreased airway resistance in piglets 8 and inhibition of human airway smooth muscle cell proliferation under in vitro conditions. 9 As alveolar structures, lung parenchymal connective tissue and airway smooth muscle properties all impact pulmonary function, one would anticipate that inhaled NO might, therefore, improve compliance and reduce airway resistance. Although previous animal studies have shown a decrease in resistance and increase in compliance [6] [7] [8] in response to NO inhalation, the effect of inhaled NO on pulmonary function in preterm infants is unclear. Therefore, the purpose of this study was to see if inhalation of NO is associated with an improvement in airway resistance and compliance in ventilated preterm infants with evolving BPD.
Some of the results of this study have been reported previously in the form of an abstract (Pediatric Research 2007).
Methods
This study included a subcohort of infants enrolled in a randomized, double-blinded, placebo-controlled multicenter study of inhaled NO in infants at substantial risk of developing BPD (The NO-CLD Study 10 ). In brief, the NO-CLD study included preterm infants, p32 weeks gestation and 500-1250 g at birth, who were receiving mechanical ventilation between 7 and 21 days of life. Exclusion criteria included life-threatening conditions, pre-existing bilateral grade 4 intraventricular hemorrhage or prior NO therapy. During enrollment, infants were randomized by the Data Coordinating Center to receive placebo or inhaled NO gas. After enrollment, an initial dose of 20 p.p.m. of study gas was delivered for 48 to 96 h with subsequent decreases to 10, 5 and 2 p.p.m. at weekly intervals with a minimum treatment duration of 24 days. Measurements of respiratory mechanics were performed at 6 of the 21 multicenter trial sites to assess the effect of NO on airway resistance and compliance. For this ancillary study, infants were eligible if they were receiving conventional mechanical ventilation at the time of enrollment. Pulmonary function measurements were made before administration of study gas (baseline period), and 1 h, 24 h and weekly after the initiation of study gas, provided the infant was still intubated. Measurements were acquired until the infant was either extubated or switched to high-frequency ventilation. Measurements were not made during high-frequency ventilation due to the frequency dependence of respiratory mechanics and active as opposed to passive expiration between the different modes of mechanical ventilation. Although it is possible to temporarily switch from high-frequency ventilation to conventional ventilation for short periods of time for measurements of respiratory mechanics, we did not feel this was in the best interest of these very-ill infants. In addition, randomization to highfrequency ventilation for as short as 24 h has been shown to effect measurements of both expiratory resistance and dynamic compliance 11 further confounding the interpretation of data collected using these two modes of ventilation. All study personnel at each site were blinded as to whether NO or placebo gas was being administered.
To minimize measurement variability, conditions were standardized. All sites used the CO 2 SMO Respiratory Profile Monitor and Analysis Plus! Software (Respironics, Wallingford, CT, USA) validated previously over the pressure and flow ranges used in this study. 12, 13 Flow was measured with a differential pressure flow sensor (accuracy ±3% over the flow range studied) and airway pressure was obtained from a pressure transducer attached to the flow sensor with a sample rate of 100 Hz. Expiratory resistance and dynamic compliance measurements of the respiratory system were calculated via the least squares technique using a singlecompartment model. To decrease intrapatient variability 14 and eliminate the need for an esophageal catheter, only mechanical breaths, as identified by the Analysis Plus! Software, were included in the analysis. As all infants were intubated with an uncuffed endotracheal tube, air leaks occurred. To minimize the effect of an air leak on resistance and compliance, only the expiratory phase of each mechanical breath with a leak of p10% was used for analysis. 12, 15, 16 If needed, infants were repositioned or had gentle pressure applied to the neck to reduce the air leak until five acceptable breaths were achieved. In 2/3 of the recording periods, it was possible to acquire more prolonged periods of acceptable data. In these cases, up to 20 breaths were averaged to represent each time period. Infants were studied with the body position and ventilator settings determined by the clinical care provider. Where clear mechanical breaths were unattainable, only the ventilator rate was increased in small increments to eliminate spontaneous breaths up to a maximum ventilator rate of 55 breaths per min. To correct for varying endotracheal tube resistance values due to the range of sizes used between infants, endotracheal tube resistance was subtracted from the expiratory resistance values. Endotracheal suctioning was performed when there was evidence of secretions present. In those cases, a minimum duration of 20 min was attained before respiratory mechanics were acquired. All measurements of compliance were normalized by weight (Ckg).
Differences in demographic variables were assessed via twosample t-test or w 2 analysis where appropriate. Comparisons of Rexp and Ckg between groups during the baseline period were performed via two-sample t-test. Changes in Rexp and Ckg between infant groups after 1 h of study gas administration were compared via two-sample t-test. Comparisons of repeated measurements of Rexp and Ckg between the control and NO infant groups over 1-and 2-week periods of study gas administration were made via a random coefficient model utilizing SAS software (Proc Mixed). A sign test was used additionally to assess whether pulmonary function parameters were 'better', defined as improvement in resistance or compliance or extubation, or 'worse', defined as deterioration in Rexp or Ckg, use of high-frequency ventilation or death, at 1 week after enrollment compared to baseline. A P-value of <0.05 was used as a level for statistical significance. This study was approved by the institutional review board at each site and written informed consent was acquired from the parents before enrollment of each infant in the study.
Results
Thirty-seven infants were randomized to receive placebo gas and 34 infants received NO. Infants in both groups were of comparable age Effect of NO on pulmonary function in infants JM Di Fiore et al at entry, birth weight, gender, race and gestational age at birth (Table 1) . There was no difference in the severity of respiratory disease at the time of enrollment as measured by a severity score (Mean airway pressure Â FiO 2 ) of 3.3±1.3 in the placebo group versus 2.9±1.5 in the NO group (P ¼ 0.25). Fifty-nine percent of the placebo group and 38% of the NO group developed BPD (P ¼ 0.07). There were no statistical differences in peak inspiratory pressure, peak expiratory pressure or ventilator rate, within each infant group over the 2 weeks of study enrollment or between infant groups. All infants had measurements of Rexp and Ckg before and 1 h after initiation of study gas. By 1 week of enrollment, eight infants in the placebo group and seven infants in the NO group were extubated and one infant in the placebo group and seven infants in the NO group were switched to high-frequency ventilation. One infant in the placebo group expired. There were seven missing data points in the placebo group and five missing data points in the NO group due to either an inability to acquire breaths meeting acceptable criteria (that is, leak >10%) or lost data due to computer hard drive failure. The number of infants with acceptable pulmonary function measurements at baseline through 2 weeks after administration of NO is shown in Table 2 . During the baseline period, values for Rexp and Ckg were comparable between the placebo and NO groups (P ¼ 0.25, Table 2 ).
To assess the acute effect of NO on measurements of pulmonary function, changes in Rexp and Ckg were assessed at 1 h after administration of study gas. As shown in Figure 1 , there was no difference between the placebo and NO groups in change in Rexp (P ¼ 0.66, two-sample t-test) or Ckg (P ¼ 0.40, two-sample t-test) over the first hour of NO administration. Previously published data from the main trial of this ancillary study have shown a decrease in the incidence of BPD in infants receiving NO at 7 to 14 days of 10 When stratifying for age at study enrollment, there was no difference in changes in Rexp between the placebo and NO group at 1 h of study gas administration at 7 to 14 (P ¼ 0.30) or 15 to 21 (P ¼ 0.14) days of life. Age at enrollment also had no effect on Ckg after 1 h of study gas administration (7 to 14 days of life, P ¼ 0.47 and 15 to 21 days of life, P ¼ 0.67).
To assess the effects of more sustained NO exposure, repeated measurements of Rexp and Ckg were made. Twenty-three infants receiving placebo gas and 15 infants receiving NO were still having pulmonary function measurements performed at 1 week of study gas administration. There was no difference between the placebo and NO groups in Rexp (P ¼ 0.63) or Ckg (P ¼ 0.29) over the first week of study gas administration (Figure 2 ). The number of infants still receiving mechanical ventilation with acceptable measurements of respiratory mechanics decreased to 16 placebo infants and 10 NO infants by 2 weeks of study gas administration. Similar to 1 week, both Rexp and Ckg remained constant over this time period with no differences between infant groups (P ¼ 0.19 and 0.45, resistance and compliance, respectively). Both groups of infants still receiving mechanical ventilation at 2 weeks showed a significant increase in body weight (both P<0.0001) during study enrollment with no difference in weight gain between groups (21±12 and 24±10%, placebo and NO groups, respectively).
The data were also analyzed to address bias due to drop out from extubation, death or high-frequency ventilation at 1 week after study enrollment. We attempted to account for whether the drop-out in the NO group was due to a clinical improvement or deterioration by categorizing infants as 'better' or 'worse' after 1 week of study gas including a separate analysis for resistance and compliance. 'Worse' was defined as any deterioration in Rexp or Ckg, death or high-frequency ventilation. 'Better' was defined as any improvement in Rexp or Ckg or extubation (Table 3) . Using this approach, there was no significant difference in respiratory status including either Rexp or Ckg in the NO group after 1 week of therapy (both P ¼ 1.0, sign test).
Discussion
This study showed no acute effect of NO on pulmonary function in our preterm infant cohort with evolving BPD. These findings are consistent with data in a smaller preterm infant cohort 17 and data Figure 2 Repeated measurements of Rexp and Ckg during study gas administration. Repeated measurements of Rexp and Ckg were documented over a 2-week period after administration of study gas. There were no differences over time or between NO and placebo over 1-or 2-week periods of study gas administration. NO, nitric oxide; Rexp, expiratory resistance. Abbreviation: HFV, high-frequency ventilation. Seven infants were not included in the data analysis due to no change in compliance (n ¼ 2), or data not meeting acceptable criteria/hard drive failure (n ¼ 5).
in older infants with respiratory syncytial virus (RSV) at 4.5 months of age. 18 Our study also showed no effect of prolonged NO administration on either Rexp or Ckg. There are no previous data addressing the prolonged effect of NO in human infants. However, both the prolonged and acute findings of this study are in marked contrast with data in immature animal models both with 6,7 and without evolving BPD. 8 In these animal models, NO has been shown to decrease resistance [6] [7] [8] and increase compliance. 6 The conflicting data on the effects of NO on pulmonary function between human infants and animal species may be due to a variety of factors including varying degrees of initial lung function, measurement conditions and heterogeneity of the population studied, including co-morbid conditions.
The contrasting results between our infant and prior animal studies may also be due to interspecies differences in lung maturation especially in the face of evolving BPD. Previous studies assessing baseline data in extremely low birth weight (<1 kg) preterm infants have shown no sequential change in respiratory mechanics over the first 4 weeks of life. 5, 19 Our study also showed no improvement in pulmonary function over the first 2 weeks of study enrollment in the placebo group. In contrast, data from the baboon model of BPD have shown improvement in pulmonary function over the first 2 weeks of life 6 even in the absence of NO treatment. This may suggest that BPD as seen in human preterm infants may incorporate pathophysiological changes not apparent in the baboon model such that pulmonary remodeling associated with preterm infants occurs over a more prolonged course. The infants in our study were also enrolled later, after the sequence of events leading to lung injury had already begun. In addition to improvements in respiratory mechanics, data in the baboon model showed an increase in lung volume in response to NO. Measurements of lung volume were not performed in this study. As both groups of infants had an increase in body weight during the 2 weeks of study enrollment it is possible that lung growth occurred during this time period.
Animal data suggest that both exogenous and endogenous NO may alter the airway bronchoconstrictor response. Animal studies in pigs and canines have shown that NO at least partially reverses histamine- 20, 21 or methacholine-induced airway constriction. [21] [22] [23] Data in rat pups have shown that endogenous NO attenuates the increase in total lung resistance induced by vagal stimulation. 24 In contrast to these animal studies with standardized bronchoconstrictor protocols, we measured longitudinal pulmonary mechanics and not specific responses to bronchoconstricting stimuli. However, long-term follow-up of this infant cohort will allow us to address the effect of early supplemental NO on subsequent clinical airway reactivity.
It is possible that measurement conditions may have masked any subtle decreases in pulmonary mechanics as measured in this study. However, every attempt was made to control these factors and minimize variability in respiratory mechanics measurements including use of the same equipment at all sites and analysis of only the expiratory phase of each mechanical breath with a leak of p10%. Additional factors including the intermittent increase in ventilator rate to inhibit spontaneous breaths, and other ventilatory parameters which were determined by the clinical care provider may have had an effect on pulmonary function measurements. However, there were no statistical differences in these parameters within or between infant groups during the 2 weeks of study enrollment. To minimize the invasiveness of this study, pulmonary function measurements were made in the body position also determined by the clinical care provider. As previous data in preterm infants prior to discharge have shown that respiratory mechanics are not affected by body position, 25 it is unlikely that this is a contributing confounder.
This study represents a subcohort of a much larger trial showing a significant decrease in the incidence of BPD in infants receiving NO versus placebo therapy. 10 Our subgroup of 71 infants, with 34 receiving NO, is a representative cohort based on demographics (race, sex, gestational age and birth weight) and a lower but not significant incidence of BPD in the NO group. Based on our infant cohort of 71 infants at 1 h after administration of NO, a post hoc analysis showed an ability to detect a 21% difference in the change in compliance and a 20% difference in the change in expiratory resistance between infant groups with 80% power and a ¼ 0.05. Previous data assessing the reproducibility of repeated pulmonary function measurements in ventilated preterm infants showed intrasubject variability during mechanical breaths of 13 to 21% for lung resistance and 13 to 15% for lung compliance. 14 Changes smaller than this magnitude are within the normal intrasubject variability, and therefore are unlikely to represent clinically relevant changes in respiratory mechanics due to NO. Thus, this study was adequately powered to detect a clinically meaningful difference (20 to 21% change) in expiratory resistance and compliance. In those infants still having pulmonary function measurements at 2 weeks of study enrollment, there was a <1% change in expiratory resistance in the placebo group and <3% improvement in the NO group. As there was no trend toward any improvement and these changes in resistance are within the error of the flow measurement, there are no data on in the current study to support a larger trial to show a clinically relevant effect during this time period of NO administration.
Due to extubation and other factors, the number of infants decreased over time thus introducing a potential source of bias. To address a possible improvement in the NO infant group by including time periods where pulmonary function data were missing, excluding technical difficulties, comparisons were made categorizing each infant as 'better' or 'worse' based on extubation, death, high-frequency oscillation or change in pulmonary function. This analysis also showed no improvement in the NO group, suggesting that patient drop-out is not causing falsenegative results.
In conclusion, NO, with an initial dose of 20 p.p.m. as used in this study, had no short-or medium-term benefits on Rexp or Ckg in mechanically ventilated preterm infants with evolving BPD. Failure to demonstrate an improvement in pulmonary function in this cohort is in clear contradistinction to data collected in animal models of this disease. These data suggest that the ovine and baboon models of airway perturbations in BPD are not homologous to the human condition. We speculate that inhaled NO may improve pulmonary outcomes in preterm infants by decreasing lung inflammation and augmenting pulmonary vascular and parenchymal maturation and the effects of NO on respiratory mechanics are not essential.
